Skip to main content
Clinical Trials/NCT02222389
NCT02222389
Completed
Not Applicable

P20 Research Project 1 Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse

Washington State University1 site in 1 country120 target enrollmentJune 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Co-Occurring Alcohol and Drug Misuse
Sponsor
Washington State University
Enrollment
120
Locations
1
Primary Endpoint
Biochemically verified alcohol and/or drug abstinence
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Contingency management (CM) is a type of treatment used in the substance abuse field. Patients' behaviors are rewarded for adherence to a treatment plan. As an approach to treatment, contingency management emerged from the behavior therapy traditions in mental health. By most evaluations, contingency management procedures produce one of the largest effect sizes out of all mental health and educational interventions.

The purpose of this study is to perform a randomized, controlled trial to evaluate the ability of a culturally-tailored contingency management (CM) intervention to increase alcohol and drug abstinence among American Indian (AI) tribal members from two rural reservations in the Northwest.

Registry
clinicaltrials.gov
Start Date
June 1, 2015
End Date
September 10, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michael McDonell

Associate Director & Associate Professor

Washington State University

Eligibility Criteria

Inclusion Criteria

  • Self-identify race as American Indian (AI)
  • Are seeking alcohol dependence and drug abuse treatment at a participating reservation
  • Are age 18 or older
  • Meet criteria of DSM-IV diagnosis of current alcohol dependence
  • Current drug misuse
  • Are not pregnant or planning to become pregnant for the duration of the study
  • Are English speaking
  • Have the ability to provide written informed consent

Exclusion Criteria

  • Have significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure during the last 12 months AND expression of concern by the patient and/or healthcare provider
  • Meet criteria for DSM-IV diagnosis of drug dependence
  • Have significant risk of dangerous drug withdrawal and/or self-reported or medically documented severe withdrawal from drugs in the last 6 months
  • Have any medical or psychiatric condition, such as organic brain disorder, dementia, or psychotic disorder, that the Principal Investigator determines would compromise safe study participation
  • Are receiving drugs under the direction of a physician for pain management or another medical condition for which drug abstinence is contraindicated

Outcomes

Primary Outcomes

Biochemically verified alcohol and/or drug abstinence

Time Frame: 24 weeks

At every study visit, urine samples will be collected and analyzed for ethyl glucuronide and drugs. This helps assess Contingency Management as a treatment for alcohol and/or drug dependence.

Secondary Outcomes

  • Self- reported data on health behaviors(24 weeks)
  • Self- reported data on alcohol and drug use(24 weeks)
  • Other substance use(24 weeks)

Study Sites (1)

Loading locations...

Similar Trials